Completed
PHASE1
INTERVENTIONAL
NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC.
Name:
Midazolam
Type:
DRUG
Description:
Administered orally.
Name:
Warfarin
Type:
DRUG
Description:
Administered orally.
Name:
Caffeine
Type:
DRUG
Description:
Administered orally.
Primary Outcomes
Measure:
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
TimeFrame:
Predose up to 24 hours postdose
Description:
PK: AUC\[0-∞\] of Midazolam
Measure:
PK: Maximum Observed Concentration (Cmax) of Midazolam
TimeFrame:
Predose up to 24 hours postdose
Description:
PK: Cmax of Midazolam
Measure:
PK: AUC[0-∞] of Warfarin
TimeFrame:
Predose up to 96 hours postdose
Description:
PK: AUC\[0-∞\] of Warfarin
Measure:
PK: Cmax of Warfarin
TimeFrame:
Predose up to 96 hours postdose
Description:
PK: Cmax of Warfarin
Measure:
PK: AUC[0-∞] of Caffeine
TimeFrame:
Predose up to 48 hours postdose
Description:
PK: AUC\[0-∞\] of Caffeine
Measure:
PK: Cmax of Caffeine
TimeFrame:
Predose up to 48 hours postdose
Description:
PK: Cmax of Caffeine
Trial Information
NCT ID
NCT05445232
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025